Trial · NCT00569127
Adverse events216
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 216
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhea | Gastrointestinal disorders | Octreotide, Bevacizumab | 16 | 197 | |
| other | Diarrhea | Gastrointestinal disorders | Octreotide, Interferon Alpha-2b | 13 | 194 | |
| other | Nausea | Gastrointestinal disorders | Octreotide, Bevacizumab | 8 | 197 | |
| other | Nausea | Gastrointestinal disorders | Octreotide, Interferon Alpha-2b | 13 | 194 | |
| other | Pain - Abdomen NOS | Gastrointestinal disorders | Octreotide, Bevacizumab | 17 | 197 | |
| other | Pain - Abdomen NOS | Gastrointestinal disorders | Octreotide, Interferon Alpha-2b | 17 | 194 | |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Octreotide, Bevacizumab | 19 | 197 | |
| other | Fatigue (asthenia, lethargy, malaise) | General disorders | Octreotide, Interferon Alpha-2b | 55 | 194 | |
| other | Leukocytes (total WBC) | Investigations | Octreotide, Bevacizumab | 5 | 197 | |
| other | Leukocytes (total WBC) | Investigations | Octreotide, Interferon Alpha-2b | 14 | 194 | |
| other | Neutrophils/granulocytes (ANC/AGC) | Investigations | Octreotide, Bevacizumab | 2 | 197 | |
| other | Neutrophils/granulocytes (ANC/AGC) | Investigations | Octreotide, Interferon Alpha-2b | 23 | 194 | |
| other | Glucose, serum-high (hyperglycemia) | Metabolism and nutrition disorders | Octreotide, Bevacizumab | 8 | 197 | |
| other | Glucose, serum-high (hyperglycemia) | Metabolism and nutrition disorders | Octreotide, Interferon Alpha-2b | 14 | 194 | |
| other | Pain - Back | Musculoskeletal and connective tissue disorders | Octreotide, Bevacizumab | 5 | 197 | |
| other | Pain - Back | Musculoskeletal and connective tissue disorders | Octreotide, Interferon Alpha-2b | 10 | 194 | |
| other | Proteinuria | Renal and urinary disorders | Octreotide, Bevacizumab | 14 | 197 | |
| other | Proteinuria | Renal and urinary disorders | Octreotide, Interferon Alpha-2b | 1 | 194 | |
| other | Hypertension | Vascular disorders | Octreotide, Bevacizumab | 60 | 197 | |
| other | Hypertension | Vascular disorders | Octreotide, Interferon Alpha-2b | 5 | 194 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00569127/events